Bicara Therapeutics Inc. (BCAX) – What Are Investment Firms Saying About This Stock?

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average rating of “Moderate Buy” from the seventeen analysts that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $30.91.

A number of research analysts recently commented on BCAX shares. The Goldman Sachs Group cut Bicara Therapeutics from a “neutral” rating to a “sell” rating and reduced their target price for the company from $20.00 to $8.00 in a research note on Friday, October 30th. Citigroup reiterated a “market outperform” rating on shares of Bicara Therapeutics in a report on Friday, August 21st. Mizuho upped their price objective on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wedbush reduced their price objective on Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating on the stock in a research report on Thursday, October 29th. Finally, BMO Capital Markets initiated coverage on Bicara Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $35.00 price objective on the stock.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX opened at $8.65 on Friday. The company’s fifty day moving average price is $18.16 and its 200-day moving average price is $20.95. The firm has a market capitalization of $572.37 million, a price-to-earnings ratio of -2.79 and a beta of -0.33. Bicara Therapeutics has a one year low of $7.87 and a one year high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.82). As a group, equities research analysts expect that Bicara Therapeutics will post -3.49 EPS for the current year.

Insiders Place Their Bets

In other Bicara Therapeutics news, CFO Ivan Hyep sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.97, for a total value of $349,625.00. Following the completion of the sale, the chief financial officer owned 129,855 shares of the company’s stock, valued at $3,632,044.35. This represents a 8.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 10,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.98, for a total transaction of $279,800.00. Following the transaction, the chief executive officer owned 362,152 shares in the company, valued at $10,133,012.96. The trade was a 2.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 58,750 shares of company stock valued at $1,554,800 over the last quarter. 13.80% of the stock is owned by corporate insiders.

Institutional Trading of Bicara Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Siren L.L.C. increased its holdings in shares of Bicara Therapeutics by 11.2% in the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock worth $115,421,000 after buying an additional 586,001 shares during the period. BlackRock Inc. purchased a new stake in Bicara Therapeutics during the 2nd quarter valued at about $114,250,000. Janus Henderson Group PLC boosted its holdings in Bicara Therapeutics by 26.2% during the 1st quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after acquiring an additional 692,933 shares during the period. Jupiter Topco LLC purchased a new stake in Bicara Therapeutics during the 2nd quarter valued at about $93,957,000. Finally, Orbimed Advisors LLC grew its position in Bicara Therapeutics by 219.1% during the 1st quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock worth $13,273,000 after acquiring an additional 458,200 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biotechnology company developing bifunctional therapies for the treatment of solid tumors. The company’s approach is designed to combine tumor-targeting activity with immune-system modulation in a single therapeutic candidate.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. The investigational therapy is designed to target epidermal growth factor receptor (EGFR) on cancer cells while simultaneously trapping transforming growth factor beta (TGF-β), a signaling protein that can contribute to tumor growth and immune suppression.